» Articles » PMID: 23843733

Elevated Preoperative Serum CA19-9 Levels in Patients with Hepatocellular Carcinoma is Associated with Poor Prognosis After Resection

Overview
Publisher Wiley
Specialty Biology
Date 2013 Jul 12
PMID 23843733
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Serum levels of the tumor marker CA19-9 have been reported to be elevated in patients with hepatocellular carcinoma (HCC), but its clinicopathologic significance is still unknown. A cohort of 304 patients undergoing surgical resection for HCC and having preoperative CA19-9 data was enrolled in this study. Serum CA19-9 levels were correlated with clinicopathologic factors. Univariate and multivariate analyses were performed to determine the predictors of patient survival. On receiver operating characteristic curve analysis, the cut off value of CA19-9 was determined to be 27 U/mL. One hundred and six patients had preoperative CA19-9 values >27 U/mL. High serum CA19-9 levels did not correlate with patient age, sex, viral status, α -fetoprotein level, tumor size, tumor grade, tumor stage, multiplicity, and vascular invasion. Patients with elevated preoperative CA19-9 levels had lower 10-year survival than those without CA19-9 elevation. Multivariate analysis revealed that CA19-9 level, tumor grade, and tumor size are independent prognostic factors for long-term survival. In conclusion, a preoperative CA19-9 value >27 U/mL is associated with poor prognosis after resection for HCC.

Citing Articles

CA19-9-related macrophage polarization drives poor prognosis in HCC after immune checkpoint inhibitor treatment.

Du T, Zou J, Yang Y, Xie H, Pang H, Zhuang W Front Oncol. 2025; 14:1528138.

PMID: 39868376 PMC: 11757246. DOI: 10.3389/fonc.2024.1528138.


The high FKBP1A expression in WBCs as a potential screening biomarker for pancreatic cancer.

Watcharanurak P, Mutirangura A, Aksornkitti V, Bhummaphan N, Puttipanyalears C Sci Rep. 2024; 14(1):7888.

PMID: 38570626 PMC: 10991374. DOI: 10.1038/s41598-024-58324-z.


Development of nomograms to predict recurrence after conversion hepatectomy for hepatocellular carcinoma previously treated with transarterial interventional therapy.

Deng M, Zhao R, Guan R, Li S, Zuo Z, Lin W Eur J Med Res. 2023; 28(1):328.

PMID: 37689775 PMC: 10492285. DOI: 10.1186/s40001-023-01310-4.


Lenvatinib plus sintilimab with or without transarterial chemoembolization for intermediate or advanced stage hepatocellular carcinoma: a propensity score-matching cohort study.

Lang M, Gan L, Ren S, Han R, Ma X, Li G Am J Cancer Res. 2023; 13(6):2540-2553.

PMID: 37424821 PMC: 10326569.


Prognostic significance of combined α-fetoprotein and CA19-9 for hepatocellular carcinoma after hepatectomy.

Zhang J, Qin S, Li Y, Lu F, Gong W, Zhong J World J Surg Oncol. 2022; 20(1):346.

PMID: 36258212 PMC: 9580117. DOI: 10.1186/s12957-022-02806-9.


References
1.
Akdogan M, Sasmaz N, Kayhan B, Biyikoglu I, Disibeyaz S, Sahin B . Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori. 2002; 87(5):337-9. DOI: 10.1177/030089160108700513. View

2.
Peng S, Chen W, Lai P, Jeng Y, Sheu J, Hsu H . High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer. 2004; 112(1):44-50. DOI: 10.1002/ijc.20279. View

3.
Zhong C, Wei W, Su X, Li H, Xu F, Guo R . Serum and tissue vascular endothelial growth factor predicts prognosis in hepatocellular carcinoma patients after partial liver resection. Hepatogastroenterology. 2012; 59(113):93-7. DOI: 10.5754/hge10638. View

4.
Tao L, Cai L, He X, Liu W, Qu Q . Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Am Surg. 2010; 76(11):1210-3. View

5.
Yuan R, Jeng Y, Pan H, Hu F, Lai P, Lee P . Overexpression of KIAA0101 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res. 2007; 13(18 Pt 1):5368-76. DOI: 10.1158/1078-0432.CCR-07-1113. View